Market
Story
Medicare Part D to Cover Eli Lilly’s Zepbound for Sleep Apnea Treatment Following FDA Approval, Creating Opportunity for $LLY
Jan 9, 2025, 02:31 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will now cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent approval by the FDA, making Zepbound the first medication specifically designed for moderate-to-severe OSA. The coverage under Medicare Part D plans presents a substantial opportunity for Eli Lilly, as it could lead to increased diagnoses and treatment of sleep apnea among patients. However, reports indicate that the costs associated with this coverage could be significant for some patients.
View original story
Similar markets
More than 300,000 • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,001 to 300,000 • 25%
$2 billion to $3 billion • 25%
$1 billion to $2 billion • 25%
Less than $1 billion • 25%
More than $3 billion • 25%
11 to 15 • 25%
More than 15 • 25%
5 to 10 • 25%
Less than 5 • 25%
26-50% reduction • 25%
51-75% reduction • 25%
76-100% reduction • 25%
0-25% reduction • 25%
Less than 40% • 25%
More than 60% • 25%
51% to 60% • 25%
40% to 50% • 25%
Yes • 50%
No • 50%
3-4 new partnerships • 25%
5 or more new partnerships • 25%
0 new partnerships • 25%
1-2 new partnerships • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
More than 60% • 25%
Less than 40% • 25%
40% to 50% • 25%
50% to 60% • 25%